54 results about "Chylomicron" patented technology

A self-emulsifying drug delivery system to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and / or mixed glycerides and / or free fatty acids containing medium and / or long chain saturated, mono-unsaturated, and / or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron delivery and optimal bioavailability to a mammalian intestinal lumen. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic / non-amphiphilic solutes to induce semi-solid formation for targeted release rates.

The present invention provides methods and compositions for modification and regulation of glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoprotein-emia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and / or atherosclerosis.

Diagnostic dry reagent tests capable of reacting with a single drop of whole blood and reporting both glucose and light-scattering analytes, such as chylomicrons, are taught. Such dry reagent tests may employ electrochemical detection methodologies, optical detection methodologies, or both methodologies. These tests alert diabetics to excessive levels of postprandial lipemia caused by meals with excessive amounts of fat, and thus can help reduce the risk of cardiovascular complications in diabetic patients.

Self-emulsifying drug delivery systems are provided to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and / or mixed glycerides and / or free fatty acids containing medium and / or long chain saturated, mono-unsaturated, and / or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron / lipoprotein delivery and optimal bioavailability through the mammalian intestinal tract. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic / non-amphiphilic solutes to induce semi-solid formation for targeted release rates.

An assay device and method for measuring the concentration of LDL-associated cholesterol in a blood-fluid sample are described. The method employs selective precipitation of VLDL and chylomicrons and immunoseparation of HDL from a blood fluid sample. The assay device allows the assay to be performed entirely in a flow strip fornat.

The invention concerns a method of preparing regression coefficients in a multivariate analysis for predicting the quantity of a component of a lipoprotein entity in a biological sample from NMR spectral data and a method of predicting the quantity of a component of a lipoprotein entity in a biological sample from NMR spectral data, which is based on the regression coefficients. The invention is especially useful for predicting the triacylglycerol level in chylomicrons of a patient.

Self-emulsifying drug delivery systems are provided to improve dissolution, stability, and bioavailability of drug compounds of dronabinol or other cannabinoids. The drug compound(s) are dissolved in an oily medium (e.g. triglycerides and / or mixed glycerides and / or free fatty acids containing medium and / or long chain saturated, mono-unsaturated, and / or poly-unsaturated free fatty acids) together with at least one surfactant. The surfactant promotes self-emulsification, thereby promoting targeted chylomicron / lipoprotein delivery and optimal bioavailability through the mammalian intestinal tract. A dosage form can optionally include co-solvents, anti-oxidants, viscosity modifying agents, cytochrome P450 metabolic inhibitors, P-GP efflux inhibitors, and amphiphilic / non-amphiphilic solutes to induce semi-solid formation for targeted release rates.

The present invention relates to an enteral composition containing phospholipids, triglycerides and cholesterol or precursors thereof, which can be used in the treatment of sepsis. With the composition of the invention the natural level of chylomicrons is maintained, in particular in gut associated lymphoid tissue (GALT), which ensures that most of LPS and / or LTA which are released in the body can be neutralized, substantially decreasing the risk of locally occurring high levels of LPS and / or LTA and thus sepsis.

The invention relates to the technical field of medical detection, in particular to a lipoprotein detection kit. The kit comprises a R1 reagent and a R2 reagent, wherein the R1 reagent is prepared from a buffer solution, BSA (Bull Serum Albumin), chylomicron dissociation agents, surfactants, sodium chloride and preservatives; the R2 reagent is prepared from a buffer solution, lipoprotein multiresistant latex microspheres, aminopropionic acid, EDTA (Ethylene Diamine Tetraacetic Acid), BSA, sugar and preservatives. The kit can effectively eliminate the interference effect of chylomicrons in samples to be tested; the accurate determination of lipoprotein in specimens with high chylomicron contents is realized; the sensitivity is high; the linear detection range is wide.

The invention provides a procalcitonin (PCT) determination kit. The kit contains a reagent R1 and a reagent R2, wherein the reagent R1 is prepared from the following components: a piperazine-1, 4-diethylsulfonic acid (PIPES) buffer solution, NaCl, MgCl2, chondroitin sulfate, hyaluronic acid, a surfactant and a preservative. And the reagent R2 is prepared from piperazine-1, 4-diethylsulfonic acid (PIPES) buffer solution, goat anti-human PCT antibody coated latex particles, a suspending aid, a stabilizer and a preservative. The invention further provides a preparation method and application of the kit, the kit can effectively avoid interference of chyle particles, latex particles of different specifications, novel surfactants and different protective agents and suspending agents are adoptedat the same time, and the kit is a liquid kit which is high in stability, high in sensitivity, good in repeatability and low in cost.

The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

The present invention is directed to one or more macromolecules in a lipid vesicle oral formulation which targets intracellular receptors, in particular for peptides, proteins, nucleic acids and mixtures thereof, optionally in combination with small molecules. The invention encapsulates said macromolecules in a neutral lipid vesicle comprised of one or more cholesteryl esters. Unique properties of macromolecules encapsulated in said vesicles include high oral bioavailability, defined herein as in at least 50%, i.e., often in excess of 50% on the basis of oral to parenteral AUC. Non-limiting examples are provided, for large hydrophilic molecules such as peptides, proteins and nucleic acids which heretofore have been very poorly absorbed by the mammalian intestine. In prior art; said molecules are generally less than 25% bioavailable, even with protective coatings and optionally absorption enhancing component substances in the formulation. An additional feature of the present invention is high tissue concentrations after oral use, a result of rapid uptake of cholestosomes delivered by chylomicrons to body cells. A preferred embodiment is disclosed for insulin, where with cholestosome encapsulation oral bioavailability is at least 66%. Prior to the present invention, oral bioavailability of insulin and other peptides and proteins was maximally 25% and usually between 5% and 10%. Additional preferred examples are provided for one or more macromolecules useful in the treatment of cancer and in particular intracellular targeting in the practice of cancer immunotherapeutics.

The invention relates to an HCV (hepatitis c virus) antibody detection reagent containing recombinant fusion antigens A and B, an application and the recombinant fusion antigens A and B, and belongs to the technical field of bioengineering. According to the HCV antibody detection reagent containing the recombinant fusion antigens A and B, the recombinant fusion antigen A contains an amino acid sequence as shown in SEQ ID NO: 2; the recombinant fusion antigen B contains an amino acid sequence as shown in SEQ ID NO: 4; the detection reagent comprises a reagent R1, a reagent R2, a reagent R3 anda reagent R4. The detection reagent has the following advantages: the two recombinant fusion antigens have the characteristics of high specificity and good stability and can be used for preparing thehepatitis C virus antibody detecting reagent by mixing in a certain ratio, and the clinical detection effect of the reagent is remarkable. Meanwhile, the detection reagent has high anti-interference capacity to chylomicron, bilirubin and hemoglobin, and can greatly meet requirements of clinical diagnosis of HCV.

The present invention provides an isolated DNA molecule that codes for a cell-surface binding protein in human monocytes and macrophages. In addition, an amino acid sequence derived from the nucleotide sequence is provided. The newly-identified cell-surface binding protein described herein is instrumental in the apoB-mediated cellular uptake of plasma chylomicrons and remnants and hypertriglyceridemic tryglyceride-rich lipoproteins in an ApoE- and lipoprotein lipase- and heparin sulfate proteoglycan-independent pathway. The present invention also provides evidence that the ligand for the receptor is within the N-terminal region of apoB-48 or B-100 at or near the lipoprotein lipase binding domain and not in a heparin binding domain.

The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

The invention relates to a dual-targeting gene treatment vector for liver cancer, which is a complex consisting of chylomicron and an eukaryotic expression plasmid vector containing an alpha-fetoprotein (AFP) promoter and a suicide gene. Apolipoprotein E (apo E) is contained in the chylomicron, and apo E receptors present on membrane surfaces of liver cells and liver cancer cells, and can identity and combine the apo E specifically, so the plasmid vector can be carried by the chylomicron specifically to be oriented to the liver cells and the liver cancer cells without being absorbed by other cells of bodies; and the eukaryotic expression plasmid vector contains the AFP promoter for promoting gene expression, and the promoter can be promoted only under the specific AFP promoting environment to promote the gene expression at the downstream of the eukaryotic expression plasmid vector, so the dual-targeting gene treatment vector has high and obvious liver cell targeting, and can be promoted and expressed only in the liver cancer cells.

The invention relates to the technical field of medical treatment, in particular to a method for separating plasma chylomicrons. The method comprises the following steps of A, freezing plasma, whereina plasma bag containing plasma is frozen, freezing time is 2-8 hours, and the freezing temperature is 40 DEG C-10 DEG C; B, standing plasma, wherein the frozen plasma bag in step A is placed upside down, and standing is conducted at 0 DEG C-4 DEG C for 8-12 hours; C, centrifuging, wherein after standing in step B, the plasma is centrifuged in a centrifuge, the centrifuge has a centrifugal force of 3900 g-4200 g, the centrifugation time is 8-12 minutes, and the centrifugation temperature is 0 DEG C-4 DEG C; D, separating, wherein the plasma in the plasma bag after centrifugation in step C is extracted to achieve separation of the plasma and the chylomicrons. The method solves the problem of separating the chylomicrons from the plasma.

Immunoreactive compositions and methods for immunizing animal, including, humans, cows, and fowl, against cholesterol and cholesterol derivatives, including cholesterol oxides, and their use in methods for reducing and preventing lipid raft-based diseases, including, but not limited to HIV-1, SARS, prion formation in Creutzfeldt-Jakob disease, and neutralizing oxidized modified lipoproteins, specifically, oxidized-LDL, oxidized-VLDL / IDL, and oxidized-chylomicrons, which contribute to the formation of fatty streaks and atherosclerotic plaques, are described.

The object of present invention is to provide a system that can deliver in vivo nucleic acids such as an siRNA for suppressing a target gene expression in vivo more safely and efficiently, and to provide an expression-suppressing agent and a pharmaceutical composition utilizing the system. An introduction substance into chylomiclon, particularly nucleic acids to which an alpha-tocopherol is bound for suppressing a target gene expression, can be delivered more safely and efficiently into hepatic cells in vivo by administering the nucleic aids under the condition where the production of chylomicron is induced in the body. Alternatively, alpha-tocopherol-bound nucleic acids are mixed with extracted chylomiclon, and then they are administered. Consequently, a target gene expression is suppressed, thereby a disease caused by an elevated expression of the target gene can be treated more safely and efficiently.

The present invention provides a preparation method and use of artificial cannabidiol chylomicron. Cannabidiol is wrapped in oil-phase cores of emulsion droplets on the premise of keeping a basic composition of simplified chylomicron. The artificial chylomicron wrapping the cannabidiol comprises the following main components: a phospholipid emulsifier, a fatty acid monoglyceride co-emulsifier, a fatty acid diglyceride co-emulsifier, cholesterol or cholic acid, cannabidiol (CBD) and a liquid oil phase. The artificial cannabidiol chylomicron can wrap the CBD in inner cores of the chylomicron, solves water solubility of the CBD and also ensures chemical stability of the CBD.

The invention relates to new application of chylomicron as a vector of a gene treatment medicament, in particular to application of chylomicron as a vector of a liver targeting gene treatment medicament. Apolipoprotein E (apo E) is contained in the chylomicron, and apo E receptors present on membrane surfaces of liver cells and liver cancer cells, and can identity and combine the apo E specifically, so a plasmid vector can be carried by the chylomicron specifically to be oriented to the liver cells and the liver cancer cells without being absorbed by other cells of bodies; and the chylomicronhas high liver cell targeting, and can be metabolized in the liver cells and the liver cancer cells without residues, so the problem of cytotoxicity is solved.

The invention belongs to the technical field of material extraction, and particularly relates to a preparation method of a high purity and low density lipoprotein. Chylomicrons and very low density lipoproteins in blood plasma are centrifuged and removed according to different densities, remain blood plasma is extracted and added withpotassium bromide and the density is adjusted to 1.045g / mL, centrifugation is carried out again to obtain a normal low density lipoprotein located at the uppermost layer, and a phosphate buffer salt solution is used for dialyzing to reduce K+ concentration; and aresultof the K+ concentration of the low density lipoprotein before and after dialyzing measured by a full-automatic biochemical analyzer is compared with a result measured by an osmotic pressure analyzer, if the K+ concentration of the low density lipoprotein is dialyzed to be with no obvious differences with the osmotic pressure of the phosphate buffer salt solution, the potassium bromide is considered to be completely dialyzed, and then the high purity and low density lipoprotein is obtained. The preparation method of the high purity and low density lipoprotein can obtain the high purity and low density lipoprotein to meet of existing experimentalrequirements.

The invention relates to a novel drug carrying and delivering system and particularly relate to a formula and a preparation method of an artificial chylomicron containing medicine carrying compound. The artificial chylomicron is prepared from the following main components: an animal oil, a vegetable oil, an oily medicine or an oil-soluble medicine, phospholipid which serves as an emulsifier, cholesterol or steroid which serves as a stabilizer, a shape control agent or a biological modifier, oleic acid or an oleate which serves a stabilizer or a co-emulsifier, fatty monoglyceride and fatty diglyceride which serve as co-emulsifiers, polyethylene glycol phospholipid derivatives (artificial chylomicron membrane protein substitutes) which serve as stabilizers and emulsifiers and are used for prolonging the half-life period of artificial chylomicron in blood, vitamin E which serves as an anti-oxidant; (8) a complex which serves as a controlling metal ion and glycerol or a carbohydrate for regulating the isotonicity of a medicinal preparation.

The present invention provides pharmaceutical compositions comprising a chylomicron and a carotenoid. The present invention also provides pharmaceutical compositions comprising a micelle and a carotenoid, suspended in an aqueous solution and suitable for intravenous administration. The bioavailability of the carotenoid of the pharmaceutical composition is higher relative to the bioavailability of free carotenoid.

This application describes novel therapeutic strategies for treating patients with hypertriglyceridemia and / or chylomicronemia based on the presence of GPIHBP1 autoantibodies. It was unexpectedly found that autoantibodies to GPIHBP1, a GPI anchored protein of capillary endothelial cells that shuttles lipoprotein lipase to its site of action in the capillary lumen, were found to be present in patients with hypertriglyceridemia, and that the autoantibodies blocked the binding of lipoprotein lipase (LPL) to GPIHBP1. Patients having hypertriglyceridemia and / or chylomicronemia and also having GPIHBP1 autoantibodies may be treated with a therapeutically effective amount of an immunosuppressive treatment and / or GPIHBP1 activator.

The invention relates to an HCV (hepatitis c virus) antibody detection reagent containing recombinant fusion antigens A and B, an application and the recombinant fusion antigens A and B, and belongs to the technical field of bioengineering. According to the HCV antibody detection reagent containing the recombinant fusion antigens A and B, the recombinant fusion antigen A contains an amino acid sequence as shown in SEQ ID NO: 2; the recombinant fusion antigen B contains an amino acid sequence as shown in SEQ ID NO: 4; the detection reagent comprises a reagent R1, a reagent R2, a reagent R3 anda reagent R4. The detection reagent has the following advantages: the two recombinant fusion antigens have the characteristics of high specificity and good stability and can be used for preparing thehepatitis C virus antibody detecting reagent by mixing in a certain ratio, and the clinical detection effect of the reagent is remarkable. Meanwhile, the detection reagent has high anti-interference capacity to chylomicron, bilirubin and hemoglobin, and can greatly meet requirements of clinical diagnosis of HCV.